Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CRESCENT BIOPHARMA, INC. (CBIO)

Crescent Biopharma outlines CR-001 ASCEND data timing and CR-002 APOLLO trial start

Neutral Impact 3 of 5 product/contract Written later

Crescent Biopharma said in an October 15, 2026 press release that it has enrolled patients in chemotherapy combination cohorts of its ASCEND trial for CR-001, and that the FDA has cleared its CR-002 ADC for a Phase 1/2 trial. The filing gives timing for several clinical data readouts but reports no revenue, earnings, or financial results, so it is a pipeline update rather than a financial report for shareholders.

Key points

  • Initial CR-001 monotherapy data from ASCEND expected in the first quarter of 2027, covering more than 125 patients
  • Chemotherapy combination cohort data anticipated in mid-2027; Phase 3 trials of CR-001 planned to start in early 2028
  • CR-002 received FDA IND clearance in October 2026; APOLLO Phase 1/2 trial planned to start in the fourth quarter of 2026, with initial data in the second half of 2027

The filing

CompanyCRESCENT BIOPHARMA, INC. (CBIO)
Form8-K, current report
Filed with the SECOct 15, 2026, 4:26 PM ET
Accession number0001628280-26-066006

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.